Sunday, March 24, 2013

INTERESTING FACTS

Most Oncologists get more practice changing information from the JCO and the New England Journal of Medicine than from BLOOD which has turned "Molecular" on them!  Blood has become more of a research tool than of impact on day to day Oncology/Hematology practice.  A balance is needed guys over there!  Even the Lancet is now better perceived by "practitioners"!
---------------------------------------------------------------------------------------------------
*Researchers keeps ahead of Oncology practice, and that is good.
While we are still coming or waking to the reality of the existence of Crizotinib.

Crizotinib

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Crizotinib
Systematic (IUPAC) name
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
Clinical data
Trade names Xalkori
MedlinePlus a612018
Licence data US FDA:link
Pregnancy cat. D (US)
Legal status -only (US)
Routes Oral
Pharmacokinetic data
Half-life 46 hours
Identifiers
CAS number 877399-52-5 
ATC code L01XE16
PubChem CID 11626560
DrugBank DB08700
ChemSpider 9801307 Yes
UNII 53AH36668S Yes
KEGG D09731 Yes
ChEMBL CHEMBL601719 Yes
Synonyms PF-02341066
1066
Chemical data
Formula C21H22Cl2FN5O 
Mol. mass 450.337 g/mol
  (what is this?)  (verify)
Crizotinib (trade name Xalkori,[1] Pfizer), is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor, approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US and some other countries, and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and children.[2]
 -------------------------------

RESEARCHERS ARE MOVING FORWARD
LOOKING NOW IN COMBINATION OF
1.  FIG-ROS1
2.  SLC34a2-ROS1
3.  COEXISTENCE  OF EGFR AND ROS1

THIS IS A GOOD SIGN.
IT IS ONCE AGAIN A SIGN OF HOW A CELLULAR PROCESS GETS COMPLICATED QUICKLY JUST AS YOU START UNDERSTANDING.

LESS THAN 0.5% OF ONCOLOGIST HAVE USED CRIZOTINIB TO DATE!
Post a Comment